Drug Type Monoclonal antibody |
Synonyms 2H-10, 2H10, CSL 346 |
Target |
Mechanism VEGF-B inhibitors(Vascular endothelial growth factor B inhibitors), Immunomodulators |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic Nephropathies | Phase 2 | US | 14 Sep 2020 | |
Diabetic Nephropathies | Phase 2 | AU | 14 Sep 2020 | |
Diabetic Nephropathies | Phase 2 | CA | 14 Sep 2020 | |
Diabetic Nephropathies | Phase 2 | IL | 14 Sep 2020 | |
Diabetic Nephropathies | Phase 2 | NZ | 14 Sep 2020 | |
Diabetic Nephropathies | Phase 2 | PR | 14 Sep 2020 |